Seven provisions. Two that help industry. Five that do not. A structured assessment of what was proposed, what is likely to pass, and what pharma companies need to do now.
On 29 April 2026, the German Federal Cabinet formally adopted the GKV-BStabG, the most significant structural change to German pharmaceutical market access in over a decade. With the statutory health insurance system projected to run a €15.3 billion deficit in 2027, the pharmaceutical sector is expected to contribute approximately €1.7 billion toward a €16.3 billion savings target. Core provisions take effect from 1 January 2027.
The legislative process has moved at exceptional speed. The formal stakeholder consultation was compressed into just 72 hours. Final parliamentary approval is targeted before the summer recess in early July 2026, leaving a narrow window for industry response.
What’s in the GKV-BStabG reform
The reform contains seven distinct provisions affecting pharmaceutical pricing and market access. The centrepiece is a dynamic manufacturer rebate that replaces the current fixed 7% rate with a variable, uncapped mechanism linked to GKV drug expenditure growth. Industry consensus projects the total rate at approximately 20% by 2030.
Alongside this, the reform introduces selective tendering for patented drugs for the first time, a statutory fallback for volume-based pricing, and new stacked rebates for vaccines. On the positive side, it removes the 2022 AMNOG price guardrails and abolishes the 20% mandatory combination discount on brand-brand therapies.
What’s at stake with the GKV-BStabG reform
Every P&MA team with German market exposure needs to understand which provisions will pass as drafted, which are likely to be narrowed, and how the combined effect reshapes the economics of patented products in Germany. The answers vary significantly by therapy area, portfolio composition, and where products sit in their lifecycle.
Read the full analysis
Our full whitepaper provides provision-by-provision analysis with Access Infinity’s independent assessment, passage probability for each measure, scenario modelling guidance, identification of the most affected companies and therapy areas, and a detailed action plan for P&MA teams.
Download the whitepaper
This blog is prepared by Access Infinity for informational purposes. All provisions described reflect the GKV-BStabG Kabinettsentwurf of 29 April 2026. The legislation remains subject to parliamentary amendment. This content does not constitute legal or financial advice.
About the authors:
Brett Gardiner
Brett is a Senior Partner at Access Infinity and brings a unique combination of clinical and academic expertise in immunology and genetics to his role in pricing and market access. He possesses a proven track record of success, managing and contributing to the development of pricing and reimbursement strategies for over 200 biopharmaceuticals, vaccines, and medical devices across all product life cycle stages.
Emily Hall
Emily is a Senior Consultant at Access Infinity. Her consulting experience focusses on pricing and access strategy across diverse disease areas and global markets. She has led multiple projects involving extensive secondary, primary and quantitative research to support clients determine pricing and access potential, clinical trial design and launch sequencing for early and late-stage assets.
